Opportunity
SAM #36C26127N0055
Award for 54 PLUVICTO Treatments for VA Northern California, with an Option for 36 More
Buyer
VA Network Contracting Office 21
Posted
October 01, 2026
Identifier
36C26127N0055
NAICS
325412, 424210
The Department of Veterans Affairs awarded a purchase of PLUVICTO for Veterans in Northern California. - Government buyer: Department of Veterans Affairs, VISN 21 and VA Northern California Health Care System; Regional Procurement Office West, Network Contracting Office 21. - OEM and vendor: Novartis Pharmaceuticals Corporation, manufacturer and supplier of PLUVICTO. - Product: 54 treatments of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), NDC 69488-0010-61, with an option for 36 additional treatments. - Use and treatment requirements: Targeted radiopharmaceutical therapy for adult Veterans with PSMA-positive metastatic castration-resistant prostate cancer. The treatment course is six cycles per Veteran, administered every six weeks. - Notable procurement condition: The VA describes the requirement as limited-source, citing the mandatory-use NAC pharmaceutical contract and the absence of another NAC distributor for the required product. - Award amount: $3,086,483.40, including an option to increase the quantity.
Description
Awardee: NOVARTIS PHARMACEUTICALS CORPORATION
Award Amount: $3,086,483.40 (including option to increase quantity)
Period of Performance: 10/01/2026 - 09/30/2027
Limited Source Justification is attached.